Join Growin Stock Community!

Abbott laboratoriesABT.US Overview

US StockHealthcare
(No presentation for ABT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ABT AI Insights

ABT Overall Performance

ABT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ABT Recent Performance

-1.83%

Abbott laboratories

0.05%

Avg of Sector

-0.31%

S&P500

ABT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ABT Key Information

ABT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ABT Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Price of ABT

ABT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ABT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.75
PE Ratio (TTM)
31.28
Forward PE
20.03
PS Ratio (TTM)
4.57
PB Ratio
3.97
Price-to-FCF
28.16
METRIC
VALUE
vs. INDUSTRY
Gross Margin
56.42%
Net Margin
14.72%
Revenue Growth (YoY)
5.67%
Profit Growth (YoY)
7.59%
3-Year Revenue Growth
4.33%
3-Year Profit Growth
5.94%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.75
PE Ratio (TTM)
31.28
Forward PE
20.03
PS Ratio (TTM)
4.57
PB Ratio
3.97
Price-to-FCF
28.16
Gross Margin
56.42%
Net Margin
14.72%
Revenue Growth (YoY)
5.67%
Profit Growth (YoY)
7.59%
3-Year Revenue Growth
4.33%
3-Year Profit Growth
5.94%

  • When is ABT's latest earnings report released?

    The most recent financial report for Abbott laboratories (ABT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ABT's short-term business performance and financial health. For the latest updates on ABT's earnings releases, visit this page regularly.

  • Where does ABT fall in the P/E River chart?

    According to historical valuation range analysis, Abbott laboratories (ABT)'s current price-to-earnings (P/E) ratio is 30.81, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ABT?

    According to the latest financial report, Abbott laboratories (ABT) reported an Operating Profit of 2.25B with an Operating Margin of 19.64% this period, representing a growth of 17.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ABT's revenue growth?

    In the latest financial report, Abbott laboratories (ABT) announced revenue of 11.46B, with a Year-Over-Year growth rate of 4.42%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ABT have?

    At the end of the period, Abbott laboratories (ABT) held Total Cash and Cash Equivalents of 7.51B, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ABT go with three margins increasing?

    In the latest report, Abbott laboratories (ABT) achieved the “three margins increasing” benchmark, with a gross margin of 57.05%%, operating margin of 19.64%%, and net margin of 15.5%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ABT's profit trajectory and future growth potential.

  • Is ABT's EPS continuing to grow?

    According to the past four quarterly reports, Abbott laboratories (ABT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ABT?

    Abbott laboratories (ABT)'s Free Cash Flow (FCF) for the period is 2.29B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ABT?

    The latest valuation data shows Abbott laboratories (ABT) has a Price-To-Earnings (PE) ratio of 30.81 and a Price/Earnings-To-Growth (PEG) ratio of 3.62. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.